Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing feels tougher than decoding laboratory notebooks. Climb Bio’s 10-K alone details pipeline science, trial setbacks, and cash runway estimates that move the stock overnight. Our platform tackles that complexity head-on, giving you Climb Bio SEC filings explained simply—in minutes, not hours.
Stock Titan’s AI reads every newly posted document on EDGAR and serves real-time insights. Need the Climb Bio quarterly earnings report 10-Q filing to gauge burn rate? AI pinpoints R&D spend and liquidity tables. Curious about an unexpected press release? The accompanying Climb Bio 8-K material events explained section highlights trial halts or partnership terms at a glance. If dilution risk matters, our summaries flag S-3 shelf registrations while linking directly to risk-factor pages. That’s understanding Climb Bio SEC documents with AI—zero jargon, full context.
Monitoring management moves is just as easy. Get push alerts for every Climb Bio insider trading Form 4 transactions; our dashboard also lists Climb Bio Form 4 insider transactions real-time so you can spot buying or selling patterns before the market reacts. The same section decodes Climb Bio executive stock transactions Form 4 against clinical milestones, adding depth to your thesis.
- Scan the Climb Bio annual report 10-K simplified to see pipeline probabilities and royalty obligations.
- Dive into Climb Bio earnings report filing analysis for quarter-over-quarter cash-burn trends.
- Review the Climb Bio proxy statement executive compensation breakdown to align incentives with long-term value.
Whether you’re a portfolio manager tracking B-cell therapy competition or a clinician-investor following APRIL biology, our AI-powered summaries, expert context, and real-time updates make each Climb Bio filing an actionable insight instead of a time sink.
Climb Bio (CLYM) reported third-quarter results marked by higher R&D investment and a solid liquidity position. Q3 net loss was $12.9 million, driven by research and development of $9.1 million and general and administrative of $5.8 million. For the nine months, net loss was $42.3 million.
Cash, cash equivalents and marketable securities were $175.8 million as of September 30, 2025, with stockholders’ equity of $177.0 million. Operating cash use was $38.7 million year to date. The company established an at‑the‑market program for up to $22.4 million and did not sell shares during the quarter. Shares outstanding were 68,184,435 as of October 31, 2025.
Pipeline progress included FDA clearance for a Phase 2 pMN study of budoprutug and an open‑label Phase 1b/2a study in ITP, with sites being activated and patients being enrolled and dosed. Climb also recorded a $9.0 million upfront expense earlier in the year for the CLYM116 license and noted milestone frameworks with Acelyrin, CRH and ProBioGen tied to future development and sales events.
Climb Bio (CLYM) filed an 8-K announcing new long-term follow-up data for budoprutug, an anti‑CD19 monoclonal antibody in development for B‑cell mediated diseases. An abstract reports results from a previously conducted Phase 1b trial (NCT04652570) in primary membranous nephropathy.
The data showed long-term control of proteinuria for up to three years after initial dosing in four patients who received up to four doses of budoprutug. Three patients required no further immunosuppressive treatment during follow-up. No treatment‑related adverse events grade 3 or higher were observed in the trial.
The company’s forward‑looking statements section references development plans for budoprutug and CLYM116 and outlines risks including clinical progress, regulatory approvals, competition, intellectual property, and capital needs.
Amendment No. 4 to a Schedule 13D updates holdings and recent sales by Access Industries affiliates in Climb Bio, Inc. The Reporting Persons collectively own 3,835,117 shares, equal to 5.66% of the 67,764,100 shares outstanding as of
Susan Altschuller, Chief Financial Officer of Climb Bio, Inc. (CLYM), received a stock option grant on October 1, 2025. The option gives the right to buy 600,000 shares of common stock at an exercise price of $1.97 per share and is exercisable through September 30, 2035. The option vests 25% on the first anniversary of the grant and the remainder in 36 equal monthly installments through October 1, 2029, subject to continued service. The reported ownership following the grant is 600,000 shares, held directly.
Climb Bio, Inc. filed an 8-K reporting an employment-related material event involving Susan Altschuller. The filing references an Offer Letter dated
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.
FAQ
What is the current stock price of Climb Bio (CLYM)?
What is the market cap of Climb Bio (CLYM)?
